|Articles|January 1, 2005

Images

images

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe

Related Content

Nicole L. Miller, MD, FACS, on assessing patients after BPH treatment failure

ByNicole L. Miller, MD, FACS

June 9th 2026

Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer

ByHannah Clarke

June 8th 2026

Study suggests potential diuretic effect with nadofaragene firadenovec

ByAbigail Keller, MD

June 8th 2026

Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026

ByClint D. Bahler, MD

June 5th 2026

The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD

ByAdam B. Weiner, MD,Chad Tang, MD

June 5th 2026

Latest CME

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Images

Related Content

Nicole L. Miller, MD, FACS, on assessing patients after BPH treatment failure

Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer

Study suggests potential diuretic effect with nadofaragene firadenovec

Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026

The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Radioligand Therapy 101: The Science Behind the Strategy

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Trending on Urology Times

Study suggests potential diuretic effect with nadofaragene firadenovec

The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD

Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer

Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026

RAD-IO: Durvalumab plus chemoradiotherapy is feasible in MIBC